RxDoctor Payments Data

Carlos Hartmann, MD

Infectious Disease · Covington, LANPI 1962769141

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $7,642 of the $9,425 with a category attached, or 81.1%. Viiv Healthcare Company accounts for 69.3% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $6,166 and has fallen 98.1% since, to $118 in 2025.

$9,425in general payments, 2019–2025

Across 59 payments — averaging $159.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$7K
  • KCI USA, Inc.$2K
  • Gilead$276
  • AbbVie$268
  • Astellas Pharma US Inc$149
  • Shionogi Inc$125
  • plus $284 from 5 others

What the payments were for

  • Speaking & faculty fees$7,64281%
  • Travel & lodging$1882%
  • Food & beverage$1,59517%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,425 in reported general payments places this provider in the 85th percentile of 105 infectious disease providers in Louisiana.

See all infectious disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$47,676
Medicare patients
184
Services billed
406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala114$439,174
GenvoyaElviteg/Cob/Emtri/Tenof Alafen36$137,561
JulucaDolutegravir/Rilpivirine39$135,391
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf29$133,546
TivicayDolutegravir Sodium44$105,651
OdefseyEmtricitab/Rilpiviri/Tenof Ala29$105,388
DovatoDolutegravir Sodium/Lamivudine18$57,970
DescovyEmtricitabine/Tenofov Alafenam15$36,602
Darunavir11$18,590
ErtapenemErtapenem Sodium28$12,959
Daptomycin43$12,275
Valganciclovir Hcl33$10,834
Atovaquone17$6,125
Linezolid28$4,602
Cefepime Hcl12$1,897

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$276$613,336165 claims
Viiv Healthcare CompanyJuluca, Tivicay, Dovato$6,532$299,012101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 105 infectious disease providers in Louisiana.

Other infectious disease in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →